SCHEMBL4776804

SCHEMBL4776804

NC(=O)c1cc2c3c(c(-c4ccccc4)[nH]c3c1)C=NNC2=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.44
PARP2 Q9UGN5 1/20 0.44
CHEK2 O96017 7/20 0.41
AURKA O14965 3/20 0.41
FYN P06241 3/20 0.41
GRK2 P25098 2/20 0.41
PLK4 O00444 2/20 0.41
ABL1 P00519 2/20 0.41
EGFR P00533 2/20 0.41
LCK P06239 2/20 0.41
CDK1 P06493 2/20 0.41
RET P07949 2/20 0.41
FGFR1 P11362 2/20 0.41
SRC P12931 2/20 0.41
FGFR3 P22607 2/20 0.41
RPS6KB1 P23443 2/20 0.41
MARK3 P27448 2/20 0.41
KDR P35968 2/20 0.41
FLT3 P36888 2/20 0.41
LIMK1 P53667 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4821015 0.91 PARP1 (0.45) PARP1PARP2CHEK2AURKAFYN
SCHEMBL4772577 0.86 PARP1 (0.46) PARP1PARP2CHEK2AURKAFYN
SCHEMBL4780114 0.86 PARP1 (0.46) PARP1PARP2CHEK2AURKAFYN
SCHEMBL4773016 0.83 PARP1 (0.47) PARP1PARP2CHEK2AURKAFYN
SCHEMBL4810799 0.83 PARP1 (0.44) PARP1PARP2CHEK2AURKAFYN
Acetic Acid SCHEMBL4773115 0.83 PARP1 (0.45) PARP1PARP2CHEK2AURKAFYN
Hydrochloric Acid SCHEMBL6105009 0.83 PARP1 (0.44) PARP1PARP2CHEK2AURKAFYN
SCHEMBL4777267 0.81 PARP1 (0.44) PARP1PARP2KDRMAPK3KDM4E
SCHEMBL4779798 0.81 IMPDH2 (0.47) PARP1PARP2CHEK2AURKAFYN
SCHEMBL4774689 0.81 IMPDH2 (0.47) PARP1PARP2CHEK2AURKAFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1947102-A1 Compositions comprising diazepinoindole derivatives as kinase inhibitors Pfizer, Inc. (US) 2008-07-23 EP disclosed
US-6967198-B2 Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy AGOURON PHARMACEUTICALS INC. (US) 2005-11-22 US disclosed